U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07109726) titled 'A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations' on July 24.

Brief Summary: This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

Study Start Date: Aug., 2025

Study Type: INTERVENTIONAL

Condition: Breast Cancer Endometrial Cancer Ovarian Cancer Lung Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma Solid Tumor Cervical Cancer

Intervention: D...